Attachment VII. — List of Quality and Efficiency Measures (included with recruitment letter)

List of Measures Included in the CMS Impact Assessment

IQR measures

Measures Requiring Abstraction and Submission by the Hospital or Its Vendor

Acute Myocardial Infarction (AMI)

- AMI-1 Aspirin at Arrival
- AMI-3 ACEI or ARB for LVSD
- AMI-5 Beta-Blocker Prescribed at Discharge
- AMI-7 Median Time to Fibrinolysis
- AMI-7a Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival
- AMI-8 Median Time to Primary PCI
- AMI-8a Timing of Receipt of Primary Percutaneous Coronary Intervention

Heart Failure (HF)

HF-2 Evaluation of LVS Function

Stroke (STK)

- STK-1 Venous Thromboembolism (VTE) Prophylaxis
- STK-2 Discharged on Antithrombotic Therapy
- STK-3 Anticoagulation Therapy for Atrial Fibrillation/Flutter
- STK-4 Thrombolytic Therapy
- STK-5 Antithrombotic Therapy By End of Hospital Day 2
- STK-6 Discharged on Statin Medication
- STK-8 Stroke Education
- STK-10 Assessed for Rehabilitation

Venous Thromboembolism (VTE)

- VTE-1 Venous Thromboembolism Prophylaxis
- VTE-2 Intensive Care Unit Venous Thromboembolism Prophylaxis
- VTE-3 Venous Thromboembolism Patients with Anticoagulation Overlap Therapy
- VTE-4 Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram
- VTE-5 Venous Thromboembolism Warfarin Therapy Discharge Instructions
- VTE-6 Hospital Acquired Potentially-Preventable Venous Thromboembolism

Pneumonia (PN)

- PN-3a Blood Cultures Performed Within 24 Hours Prior to or 24 Hours After Hospital Arrival for Patients Who Were Transferred or Admitted to the ICU Within 24 Hours of Hospital Arrival
- PN-6 Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patient
- PN-6a Initial Antibiotic Selection for CAP in Immunocompetent ICU Patient
- PN-6b Initial Antibiotic Selection for CAP in Immunocompetent Non–ICU Patient

Children's Asthma Care (CAC)

- CAC-1 Relievers for Inpatient Asthma
- CAC-2 Systemic Corticosteroids for Inpatient Asthma
- CAC-3 Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver

Surgical Care Improvement Project (SCIP)

- SCIP-Inf-1 Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision
- SCIP-Inf-2 Prophylactic Antibiotic Selection for Surgical Patients
- SCIP-Inf-3 Prophylactic Antibiotics Discontinued Within 24 Hours After Surgery End Time
- SCIP-Inf-4 Cardiac Surgery Patients With Controlled Postoperative Blood Glucose
- SCIP-Inf-6 Surgery Patients with Appropriate Hair Removal
- **SCIP-Inf-9** Urinary Catheter Removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero (8,13)
- SCIP-Card-2 Surgery Patients on Beta-Blocker Therapy Prior to Arrival Who received a Beta-Blocker During the Perioperative Period (6,12)
- SCIP-VTE-2 Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis Within 24 Hours Prior to
- Surgery to 24 Hours After Surgery (3,12)

Emergency Department (ED)

- **ED-1a** Median Time from ED Arrival to ED Departure for Admitted ED Patients Overall Rate
- ED-1b Median Time from ED Arrival to ED Departure for Admitted ED Patients Reporting Measure
- ED-1c Median Time from ED Arrival to ED Departure for Admitted ED Patients –
 Observation Patients
- **ED-1d** Median Time from ED Arrival to ED Departure for Admitted ED Patients Psychiatric/Mental Health Patients
- ED-2a Admit Decision Time to ED Departure Time for Admitted Patients Overall Rate
- **ED-2b** Admit Decision Time to ED Departure Time for Admitted Patients Reporting Measure (9,10)
- ED-2c Admit Decision Time to ED Departure Time for Admitted Patients -Psychiatric/Mental Health Patients

Immunization (IMM)

- IMM-1a Pneumococcal Immunization Overall Rate
- IMM-1b Pneumococcal Immunization Age 65 and older
- IMM-1c Pneumococcal Immunization High Risk Populations (Age 5 through 64 years)
- IMM-2 Influenza Immunization

Healthcare Associated Infection Measure (HAI)

- Central-Line Associated Bloodstream Infection (CLABSI)
- Surgical Site Infection (SSI-colon, SSI-abdominal hysterectomy)
- Catheter-Associated Urinary Tract Infection (CAUTI)
- MRSA Bacteremia (10) Clostridium Difficile (C.difficile)
- Healthcare Personnel Influenza Vaccination

Hospital Consumer Assessment of Healthcare Providers and Systems Survey (HCAHPS)

Hospital Consumer Assessment of Healthcare Providers and Systems Survey

Tobacco Treatment (TOB)

- TOB-1 Tobacco Use Screening
- TOB-2 Tobacco Use Treatment Provided or Offered
- TOB-2a Tobacco Use Treatment
- TOB-3 Tobacco Use Treatment Provided or Offered at Discharge
- TOB-3a Tobacco Use Treatment at Discharge
- TOB-4 Tobacco Use: Assessing Status After Discharge

Substance Use

- (SUB)SUB-1 Alcohol Use Screening
- SUB-2 Alcohol Use Brief Intervention Provided or Offered
- **SUB-2a** Alcohol Use Brief Intervention

- SUB-3 Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge
- SUB-3a Alcohol and Other Drug Use Disorder Treatment at Discharge
- SUB-4 Alcohol and Drug Use: Assessing Status after Discharge

Measures Requiring Web-Based Hospital Data Entry

Structural Measures

- Participation in a Systematic Database for Cardiac Surgery
- Participation in a Systematic Clinical Database Registry for Stroke Care
- Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care
- Participation in a Systematic Clinical Database Registry for General Surgery

Data Accuracy and Completeness Acknowledgement

Data Accuracy and Completeness Acknowledgement

Perinatal Care

• **PC-01** Elective Delivery Prior to 39 Completed Weeks Gestation: Percentage of Babies Electively Delivered Prior to 39 Completed Weeks Gestation

Measure Information Obtained from Claims-Based Data

Mortality Measures (Medicare patients)

- MORT-30-AMI Acute Myocardial Infarction (AMI) 30-Day Mortality Rate
- MORT-30-HF Heart Failure (HF) 30-Day Mortality Rate
- MORT-30-PN Pneumonia (PN) 30-Day Mortality Rate
- MORT-30-COPD Chronic Obstructive Pulmonary Disease (COPD) 30-Day Mortality Rate
- MORT-30-STK Acute Ischemic Stroke (STK) 30-Day Mortality Rate

Readmission Measures (Medicare patients)

- READM-30-AMI Acute Myocardial Infarction (AMI) 30-Day Readmission Rate
- **READM-30-HF** Heart Failure (HF) 30-Day Readmission Rate
- READM-30-PN Pneumonia (PN) 30-Day Readmission Rate
- Hip/Knee Readmission Hospital-Level 30-Day All-Cause Risk- Standardized Readmission Rate (RSRR) Following Elective Total Hip Arthroplasty (THA)/Total Knee Arthroplasty (TKA)
- **HWR** Hospital-Wide All-Cause Unplanned Readmission (HWR)
- READM-30-COPD Chronic Obstructive Pulmonary Disease (COPD) 30-Day Readmission Rate
- READM-30-STK Stroke (STK) 30-Day Readmission Rate

Agency for Healthcare Research and Quality (AHRO) Measures

- PSI 90 Complication/Patient Safety for Selected Indicators
- PSI 4 Death Among Surgical Patients with Serious Treatable Complications (Harmonized with Nursing Sensitive Care Measure, Failure to Rescue)

Surgical Complications

Hip/Knee Complications Hospital-Level Risk-Standardized Complication Rate (RSCR)
 Following Elective Primary Total Hip Arthroplasty (THA) and Total Knee Arthroplasty
 (TKA)

Cost Efficiency Measures

- Medicare Spending per Beneficiary (MSPB)
- Acute Myocardial Infarction (AMI) Payment per Episode of Care

<u>Measures for Electronic Reporting via Certified Electronic Health Record Technology</u> (<u>CEHRT</u>) (voluntary participation CY 2014)

- **STK-2** Discharged on Antithrombotic Therapy
- STK-3 Anticoagulation Therapy for Atrial Fibrillation/Flutter
- **STK-4** Thrombolytic Therapy
- STK-5 Antithrombotic Therapy By End of Hospital Day 2
- STK-6 Discharged on Statin Medication
- **TK-8** Stroke Education
- STK-10 Assessed for Rehabilitation
- VTE-1 Venous Thromboembolism Prophylaxis
- VTE-2 Intensive Care Unit Venous Thromboembolism Prophylaxis
- VTE-3 Venous Thromboembolism Patients with Anticoagulation Overlap Therapy
- VTE-4 Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or NomogramV
- TE-5 Venous Thromboembolism Warfarin Therapy Discharge Instructions
- VTE-6 Hospital Acquired Potentially-Preventable Venous Thromboembolism (10,14)
- ED-1 Median Time from ED Arrival to ED Departure for Admitted ED Patients
- ED-2 Admit Decision Time to ED Departure Time for Admitted Patients
- PC-01 Elective Delivery Prior to 39 Completed Weeks Gestation: Percentage of Babies Electively Delivered Prior to 39 Completed Weeks Gestation

OQR measures

Cardiac Care (AMI and CP) Measures

- **OP-1:** Median Time to Fibrinolysis
- **OP-2:** Fibrinolytic Therapy Received Within 30 Minutes
- OP-3: Median Time to Transfer to Another Facility for Acute Coronary Intervention
- OP-4: Aspirin at Arrival
- OP-5: Median Time to ECG

Surgery

- OP-6 Timing of Antibiotic Prophylaxis
- OP-7 Antibiotic Selection

Imaging Efficiency Measures

- OP-8: MRI Lumbar Spine for Low Back Pain
- OP-9: Mammography Follow-up Rates
- **OP-10**: Abdomen CT Use of Contrast Material
- OP-11: Thorax CT Use of Contrast Material
- OP-13: Cardiac Imaging for Preoperative Risk Assessment for Non Cardiac Low Risk Surgery
- OP-14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT

ED-Throughput

- OP-18 Median Time from ED Arrival to ED Departure for Discharged ED Patients
- OP-20 Door to Diagnostic Evaluation by a Qualified Medical Professional
- OP-22 Left Without Being Seen

Pain Management

• OP-21 Median Time to Pain Management for Long Bone Fracture

Stroke

 OP-23 Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival

Structural and Web-Based Measures

- **OP-12:** The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into their ONC-Certified EHR System as Discrete Searchable Data
- **OP-17:** Tracking Clinical Results between Visits
- **OP-25:** Safe Surgery Checklist Use
- OP-26: Hospital Outpatient Volume Data on Selected Outpatient Surgical Procedures
- **OP-27:** Influenza Vaccination Coverage among Healthcare Personnel
- OP-29 Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk
- **OP-30** Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use
- OP-31 Cataracts Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery